Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Goldman sees FTSE 100 hitting 9,000 on potential Ukraine peace deal

(Sharecast News) - Goldman Sachs has hiked its price forecasts for the pan-European Stoxx 600 and London's FTSE 100 on the back of a potential peace deal for Ukraine, predicting that the UK index could hit the 9,000 level within 12 months. The speculation comes after US president Donald Trump said he would start negotiating with Vladimir Putin regarding a potential end to the Russia-Ukraine war, which began escalating in early 2022. Betting market odds of a ceasefire this year have risen to 70%, Goldman noted.

The bank predicts a "modest" re-rating of European equities if a deal with Russia is struck, but highlighted that the outcome of peace talks is still uncertain and earnings prospects for Europe have not materially improved regardless.

"Since Russia's full-scale invasion of Ukraine in February 2022, the STOXX 600 has underperformed S&P 500 and MSCI World by 13% and 6% respectively. Flows into European equities have also been consistently weak since the war began, with outflows in almost every week since the February 2022 invasion," Goldman said in a research note on Friday.

The impact of a potential peace deal for European equities would be lower risk premiums, lower energy prices, better consumer confidence and stronger economic growth, Goldman said, estimating that European GDP should increase by 0.2% in a limited ceasefire scenario and by 0.5% in an upside scenario.

The bank has lifted its three-month, six-month and 12-month price forecasts for the Stoxx 600 to 560, 570 and 580, respectively, up 40 points from previous estimates.

Three-month, six-month and 12-month price forecasts for the FTSE 100 have all risen by 400 points to 8,800, 8,900 and 9,000, respectively.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.